1. Home
  2. |Insights
  3. |ASBCA Rejects the Government’s Use of "Prior Material Breach" Affirmative Defense

ASBCA Rejects the Government’s Use of "Prior Material Breach" Affirmative Defense

Client Alert | 1 min read | 09.24.19

In Engility, LLC, ASBCA No. 61281 (August 19, 2019), the ASBCA denied the government’s motion to amend its answer to include the affirmative defense of prior material breach. The matter involved the government’s disallowance of settlement costs paid by Engility following a lawsuit in which Iraqi plaintiffs alleged that Engility’s employees engaged in abuse at Abu Ghraib. Before the government’s motion, the parties had engaged in costly and time consuming discovery after the government argued that under Geren v. Tecom, Inc., 566 F.3d 1037 (Fed. Cir. 2009), Engility had to demonstrate that none of its employees engaged in the alleged abusive conduct, and therefore the Iraqi plaintiffs had very little likelihood of success on the merits. Engility opposed the government’s motion to amend its answer because, among other reasons, the amendment would exponentially expand the scope of already extensive discovery. The ASBCA requested supplemental briefing on the government’s motion, which clarified the government’s position: the affirmative defense of Engility’s alleged prior material breach would be invoked only in the event the Board found that Engility’s settlement costs were allowable and, thus, the government’s disallowance would breach the contract’s Allowable Cost and Payment clause. The government also stated that it did not intend to argue that Engility’s alleged prior material breach was related to the Iraqi plaintiff’s allegations.  In denying the motion, the Board stated that “It is a legal impossibility for the government to raise the affirmative defense of prior material breach as a defense against what the government itself admits is essentially the possibility that its own claim may fail.” 

Insights

Client Alert | 15 min read | 08.20.25

The New EU “Pharma Package”: Interplay with the Critical Medicines Act and other shortage initiatives

In this eighth alert in our weekly series on the EU Pharma Package, we continue our overview of initiatives with respect to security of supply and shortage prevention and mitigation. Our last alert looked at how the Pharma Package seeks to address these issues. However, the Pharma Package does not exist in isolation, and in this alert we will discuss the interplay between its measures and those contained in other important EU initiatives such as the proposed Critical Medicines Act (CMA), and the Medicinal Countermeasures Strategy and the EU Stockpiling Strategy....